Medtronic's Diabetes Unit MiniMed Files for IPO, Set to Launch as Independent Company on Nasdaq

On December 19, 2025, Medtronic officially announced that its diabetes business unit, MiniMed, had submitted a registration statement (Form S-1) for an initial public offering (IPO) to the U.S. Securities and Exchange Commission (SEC).Marks the official launch of the independent listing process for this business with a 40-year history in diabetes care.

MiniMed Plans to Go Public on Nasdaq Under the Ticker "MMED"; Offering Size and Price Range to Be Determined Based on Market Conditions After SEC Review. On the business side, the independent MiniMed will continue to deepen its diabetes management product line.Including automatic insulin pumps, smart insulin pens, and continuous glucose monitors (CGM), etc.

From a timeline perspective, Medtronic did so this year.End of MayAnnounced plans to spin off its diabetes division, with the split expected to be completed within the next 18 months. The move aims to create a "more focused Medtronic," and the newly separated company will be renamed "MiniMed," reviving the name of the insulin pump company acquired in 2001.

MiniMed's Over 40-Year History

The new company's headquarters will remain in Northridge, California, with more than 8,000 employees. Currently, the diabetes business accounts for 8% of Medtronic's fiscal year 2025 revenue and 4% of the company's divisional operating profit.

JuneMedtronic announces an investment of 4.3 billion rupees (approximately 360 million RMB) into a new Global Capability Center (GCC) for diabetes in Pune, India, over the next five years, creating over 300 service and software jobs in the first year.Plan to double the number of positions within four years.

On September 2, Medtronic's core diabetes management product, the MiniMed™ 780G Automated Insulin Delivery System, received two key approvals from the U.S. FDA, marking a significant breakthrough in the system's applicable population and technical compatibility.

In December 2025, Ryan Weispfenning, the former head of Medtronic's investor relations, officially transitioned to a new role, taking full responsibility for the investor relations function of the independent MiniMed. As a seasoned professional with over 25 years of experience at Medtronic and 10 years of leadership in the investor relations team, he has been recognized by the company as a key figure in building strong relationships with global investors and analysts.

Weispfenning himself stated, "Having led Medtronic's investor relations efforts over the past decade, I am now honored to help MiniMed establish an independent investor relations function and communicate its long-term strategy and growth commitment as a standalone public company to investors."